Jakimovski Dejan, Weinstock-Guttman Bianca, Ramanathan Murali, Kolb Channa, Hojnacki David, Minagar Alireza, Zivadinov Robert
a Buffalo Neuroimaging Analysis Center, Department of Neurology , Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York , Buffalo , NY , USA.
b Jacobs MS Center, Department of Neurology , Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York , Buffalo , NY , USA.
Expert Opin Biol Ther. 2017 Sep;17(9):1163-1172. doi: 10.1080/14712598.2017.1347632. Epub 2017 Jul 3.
Multiple sclerosis (MS) is the most common neurological disease responsible for early disability in the young working population. In the last two decades, based on retrospective/prospective data, the use of disease-modifying therapies has been shown to slow the rate of disability progression and prolonged the time to conversion into secondary-progressive MS (SPMS). However, despite the availability of several approved therapies, disability progression cannot be halted significantly in all MS patients. Areas covered: This article reviews the immunopathology of the B-cells, and their role in pathogenesis of MS and their attractiveness as a potential therapeutic target in MS. The review focuses on the recently published ocrelizumab phase III trials in terms of its efficacy, safety, and tolerability as well as its future considerations. Expert opinion: B lymphocyte cell depletion therapy offers a compelling and promising new option for MS patients. Nonetheless, there is a need for heightened vigilance and awareness in detecting potential long-term consequences that currently remain unknown.
多发性硬化症（MS）是导致年轻劳动人口早期残疾的最常见神经系统疾病。在过去二十年中，基于回顾性/前瞻性数据，已证明使用疾病修正疗法可减缓残疾进展速度，并延长转化为继发进展型多发性硬化症（SPMS）的时间。然而，尽管有几种获批疗法可供使用，但并非所有MS患者的残疾进展都能得到显著遏制。涵盖领域：本文综述了B细胞的免疫病理学及其在MS发病机制中的作用，以及其作为MS潜在治疗靶点的吸引力。该综述重点关注最近公布的奥瑞珠单抗III期试验的疗效、安全性和耐受性以及未来考量。专家观点：B淋巴细胞清除疗法为MS患者提供了一个引人关注且前景广阔的新选择。尽管如此，在检测目前尚不清楚的潜在长期后果方面，仍需要提高警惕并加强认识。
